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Abstract
Cryptophycins are cytotoxic natural products that exhibit considerable activities even against multi-drug-resistant tumor cell lines.
As fluorinated pharmaceuticals have become more and more important during the past decades, fluorine-functionalized crypto-
phycins were synthesized and evaluated in cell-based cytotoxicity assays. The unit A trifluoromethyl-modified cryptophycin proved
to be highly active against KB-3-1 cells and exhibited an IC50 value in the low picomolar range. However, the replacement of the
3-chloro-4-methoxyphenyl-substituent in unit B by a pentafluorophenyl moiety resulted in a significant loss of activity.
Introduction
Cryptophycins form a class of cytotoxic sixteen-membered
macrocyclic depsipeptides. Cryptophycin-1 (1) was isolated for
the first time in 1990 from cyanobacteria Nostoc sp.
ATCC 53789 [1] (Figure 1). Moore et al. isolated cryptophycin-
1 from the related Nostoc strain GSV 224, investigated the
stereochemistry, and described the cytotoxicity [2]. At the same
time Kobayashi et al. succeeded in a full structural analysis and
described the first total synthesis of another member of the
cryptophycin family [3,4]. Twenty-eight naturally occurring
cryptophycins have been isolated up to this day [5-7], while
numerous synthetic analogues have been synthesized in the
frame of structure–activity-relationship studies [8,9]. Crypto-
Figure 1: Structures of cryptophycin-1 (1) and -52 (2).
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Figure 2: Fluorinated derivatives of cryptophycin-1 and -52 [20-22].
phycins display remarkable biological activity against multi-
drug-resistant (MDR) tumor cells. Such tumor cells express a
P-glycoprotein, a drug efflux pump that transports xenobiotics
out of the cell. A synthetic analogue, cryptohycin-52 (2,
LY355703), has been investigated in clinical trials. However,
this development was discontinued because of neurotoxic side
effects and lacking efficacy in vivo [10,11].
Fluorinated drugs are gaining increasing importance, and
currently about 20% of all pharmaceuticals on the world market
contain fluorine substituents [12,13]. Fluorination is supposed
to enhance bioavailability and receptor selectivity. The van der
Waals-radius of a fluorine substituent (1.47 Å) lies between the
value of a hydrogen substituent (1.20 Å) and an oxygen
substituent (1.52 Å). However, despite this similarity in size, a
fluorine substituent exerts considerable electronic effects due to
the high electronegativity. A trifluoromethyl substituted
analogue of epothilone, another important tubulin-binding cyto-
toxic drug, was shown to retain the cytotoxic activity of the
parent compound. At the same time nonspecific side effects due
to oxidative degradation were prevented by the introduction of
the CF3 group [14,15]. Likewise, partially fluorinated taxoids,
analogues of paclitaxel and docetaxel, displayed biological
activity even exceeding that of the parent nonfluorinated com-
pounds [16]. The interesting biological profile of fluorinated
cytotoxic agents prompted us to synthesize partially fluorinated
analogues of cryptophycins.
The depsipeptidic character of the cryptophycins suggests four
different fragments to be assembled in the total synthesis,
named unit A–D (Figure 1). Unit A is an α,β-unsaturated
δ-hydroxy acid that usually also contains a benzylic epoxide or
a benzylic double bond. Unit B represents a chlorinated
O-methyl-D-tyrosine derivative, while unit C is a β2-amino
acid, usually β2-homoalanine. Finally, unit D is leucic acid, the
hydroxy analogue of leucine. Numerous synthetic analogues
have been obtained in the frame of structure–activity-relation-
ship studies (SAR-studies), as reviewed in [17,18].
Unit A para-alkoxymethyl derivatives of cryptophycin-52 have
been synthesized and were shown to retain cytotoxicity even
against MDR tumor cell lines [19]. The introduction of a fluo-
rine substituent in the same position also provides a cytotoxic
analogue, albeit with decreased biological activity by a factor of
5 [8].
In unit B the chlorine and the methoxy substituents at the
D-tyrosine residue were crucial for high antimitotic activity
[17,18]. Moore et al. patented the synthesis of fluorinated
analogues of cryptophycin-1 and cryptophycin-52 [20]. In
particular, derivative 3 was shown to retain biological activity
(IC50 = 39 pM) and was active against the tumor cell
line KB-3-1 [21] (Figure 2). The chlorohydrin derived from 4
that also contained a fluorine substituent in the para-position of
the unit A phenyl ring was patented as a promising candidate
[22].
In the frame of our on-going SAR studies on cryptophycins
[19,23-30], we envisaged the synthesis of analogues of crypto-
phycin-52 with a para-trifluoromethyl substituent at the unit A
aryl ring. In addition, we targeted the replacement of the unit B
by a D-pentafluorophenylalanine residue.
Results and Discussion
Cryptophycin-52 with a para-trifluoromethyl
substituted unit A
The synthesis of the para-trifluoromethyl substituted unit A
started with a modified Knoevenagel condensation [23,31]. The
required aldehyde 9 was obtained by DIBAL-H reduction of the
corresponding methyl ester 8 and was found to decompose upon
chromatographic purification (Scheme 1). However, it can
usually be employed in the Knoevenagel condensation without
purification. Reaction of 9 with malonic acid in the presence of
piperidine/acetic acid gave the β,γ-unsaturated carboxylic acid
10. The latter compound was transformed into the methyl ester
by treatment with SOCl2 in methanol. The resulting ester 11
could then be directly employed without purification in the
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Scheme 1: Access to the trifluoromethyl substituted unit A-building block 16. Reagents and conditions: (a) SOCl2, MeOH, 0 °C → rt, 16 h; (b)
DIBAL-H, CH2Cl2, −78 °C, 3.5 h; (c) malonic acid, piperidine, AcOH, DMSO, 65 °C, 1.5 h; (d) SOCl2, MeOH, 0 °C → rt, 1 h; (e) K2CO3,
K2OsO4∙2H2O, K3[Fe(CN)6], (DHQD)2-PHAL, CH3SO2NH2, t-BuOH/H2O, 0 °C, 42 h; (f) LDA, MeI, THF, −78 °C, 3 d; (g) (CH3)2C(OCH3)2, MeOH,
Amberlyst-15®, rt, 8 d; (h) DIBAL-H, CH2Cl2, −78 °C, 4.5 h; (i) AllylSnBu3, MgBr2∙Et2O, CH2Cl2, −78 °C, 15 h.
asymmetric dihydroxylation with osmium tetroxide and
(DHQD)2PHAL, in close analogy to a previously published
procedure [23]. The initially formed vicinal diol cyclizes under
the reaction conditions to give lactone 12 in enantiomerically
pure form (chiral HPLC: Chiralpak OD®). Deprotonation of 12
with 2.5 equiv of LDA, followed by treatment with
iodomethane furnished the α-methyl substituted lactone 13.
Treatment of this compound with acetone dimethyl acetal in
methanol in the presence of an acidic ion exchanger resulted in
acetonide protection of the vicinal diol, accompanied by methyl
ester formation. The methyl ester 14 was subsequently reduced
with DIBAL-H to give the aldehyde 15. In order to avoid
epimerisation, this aldehyde was not purified, but filtered
through Celite only and then reacted with allyl-tri-n-butyltin to
give the homoallyl alcohol 16. The magnesium bromide diethyl
etherate mediated allylation proceeded under substrate control
and with complete diastereoselectivity [23,32].
Cross-metathesis of homoallyl alcohol 16 with the unit B
derived acrylamide 17 provided the α,β-unsaturated δ-hydroxy
carboxamide 18 (Scheme 2). In order to bring about complete
metathesis of 16, the acrylamide 17 had to be employed in 1.2-
fold excess, which resulted in a contamination of the cross-
metathesis product 18 with minor amounts of the homo-
coupling product 23. The latter could not be separated by flash
chromatography on this stage, but did not interfere with the
subsequent Yamaguchi esterification of 18 with the unit C–D
segment 19 and was removed on this stage [33]. Fmoc cleavage
of the seco-depsipeptide 20 liberated the free amino group of
unit C, which under the reaction conditions displaced the
trichloroethylester of unit B resulting in macrocyclization
according to Moher et al. [34]. In the final steps the dioxolane
ring of 21 was cleaved with trifluoroacetic acid in the presence
of water. The resulting vicinal diol was not purified, but reacted
with a large excess of trimethyl orthoformate. The cyclic
orthoester resulting from this transformation was directly
subjected to reaction with acetyl bromide to form a bromohy-
drin formate. This was then treated with a potassium carbonate/
ethylene glycol/dimethoxyethane-emulsion to bring about
cleavage of the formyl ester accompanied by epoxide forma-
tion as previously described by us [19]. The trifluoromethyl
substituted cryptohycin-52 analogue 22 was obtained in a yield
of 39% over the final four steps. It was purified by column
chromatography, followed by lyophilization.
Cryptophycin-52 with D-pentafluorophenyl-
alanine as unit B
The N-acryloyl derivative 26 of D-pentafluorophenylalanine
was obtained by carbodiimide esterification of commercially
available Boc-D-pentafluorophenylalanine (24) with
trichloroethanol, followed by cleavage of Boc and reaction with
acryloylchloride in the presence of base [19] (Scheme 3).
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Scheme 2: Assembly of units A–D and macrocyclization, followed by diol-epoxide transformation to give the trifluoromethyl substituted analogue 22 of
cryptophycin-52. Reagents and conditions: (a) Grubbs II catalyst, CH2Cl2, reflux, 16 h; (b) 19, DMAP, NEt3, 2,4,6-trichlorobenzoylchloride, THF, 0 °C,
1 h; (c) piperidine, DMF, rt, 16 h; (d) TFA, CH2Cl2, H2O, 0 °C, 3 h; (e) (CH3O)3CH, PPTS, CH2Cl2, rt, 2 h; (f) AcBr, CH2Cl2, rt, 4 h; (g) K2CO3, DME,
ethylene glycol, rt, 3 min.
Scheme 3: Synthesis of the pentafluorophenylalanine building block 26. Reagents and conditions: (a) pyridine, trichloroethanol, DCC, CH2Cl2, 0 °C,
20 h; (b) 1. TFA, rt, 2 h; 2. NEt3, acryloylchloride, CH2Cl2, 0 °C, 7 h.
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Scheme 4: Convergent synthesis of the pentafluorinated cryptophycin 31. Reagents and conditions: (a) Grubbs II catalyst, CH2Cl2, reflux, 16 h; (b)
19, DMAP, NEt3, 2,4,6-trichlorobenzoylchloride, THF, 0 °C, 1 h; (c) piperidine, DMF, rt, 16 h; (d) TFA, CH2Cl2, H2O, 0 °C, 3 h; (e) (CH3O)3CH, PPTS,
CH2Cl2, rt, 2 h; (f) AcBr, CH2Cl2, rt, 4 h; (g) K2CO3, DME, ethylene glycol, rt, 3 min.
The cryptophycin analogue with D-pentafluorophenylalanine as
unit B was synthesized by the same convergent route as
described for derivative 22. Homoallyl alcohol 27 [23] was
reacted with the D-pentafluorophenylalanine derivative 26 in a
cross-metathesis reaction in the presence of Grubbs II catalyst
(Scheme 4). The resulting α,β-unsaturated δ-hydroxy carbox-
amide 28, representing units A and B was then esterified with
19 under Yamaguchi conditions with 2,4,6-trichloroben-
zoylchloride and triethylamine in the presence of catalytic
amounts of DMAP. Macrocyclization was brought about by
cleavage of the Fmoc protecting group from the unit C amino
group, which concomitantly displaced the trichloroethylester at
unit B to result in the macrocyclic product 30 [34]. Cleavage of
the dioxolane liberated the vicinal diol, which was then
subjected to the final diol-epoxide transformation to provide the
cryptophycin-52 analogue 31 in a yield of 14% over the final
four steps.
The biological activities of the fluorine-functionalized crypto-
phycin analogues were determined in a resazurin assay with the
Table 1: Cytotoxicity of the fluorinated cryptophycins 22 and 31 in
comparison to cryptophycin-52 (2).
IC50 [pM]
(KB-3-1)
IC50 [nM]
(KB-V1) FR
2 15.5 0.26 16.7
22 66.0 10.1 153
31 2970 98.4 33
tumor cell line KB-3-1 and its MDR correlate KB-V1. The IC50
values of the fluorinated cryptophycins 22 and 31 were
compared to cryptophycin-52 in Table 1 [17]. While the cyto-
toxicity of the unit A-modified analogue 22 against the tumor
cell line KB-3-1 was only by about a factor of 4 decreased
compared to cryptophycin-52, the pentafluorophenylalanine-
containing derivative 31 was much less active. A significant
loss in activity of both analogues against the MDR cell line
KB-V1 was observed. The degree of activity against MDR
tumor cells can be described by the resistance factor FR, which
Beilstein J. Org. Chem. 2012, 8, 2060–2066.
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is defined as the ratio of the IC50 value for the MDR cell line
and the value for the nonresistant cell line. A high FR means a
high loss of activity due to the cellular resistance mechanisms.
Analogue 22 exhibited a high FR value whereas compound 31
showed a lower loss of activity.
Conclusion
The synthesis of selectively fluorinated cryptophycin-52
analogues succeeded and both target compounds could be
obtained. The two analogues were less active, both against the
tumor cell line KB-3-1 and its MDR subclone KB-V1. This fact
was quite surprising because the fluorinated cryptophycins were
expected to display higher lipophilicity compared to the parent
compound cryptophycin-52 and, therefore, exhibit equal or
even higher activities. In contrast, more amphiphilic or polar
compounds are usually good substrates for the P-glycoprotein
efflux pump resulting in a decreased bioactivity.
Supporting Information
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Full experimental procedures and detailed analytical data
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